NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its second-quarter revenues were down less than 1 percent year over year, but its BD Biosciences segment managed three percent revenue growth for the quarter.
The Franklin Lakes, NJ-based maker of diagnostics, medical products, and life science research tools reported revenues of $1.74 billion for the three-month period ended March 31, down from revenues of $1.75 billion in the second quarter of 2008.
Its Biosciences business segment had revenues of $303.8 million for the quarter, up 3 percent from revenues of $294.1 million for Q2 2008. The segment's revenues include a .7 percent positive impact from currency translation.
The BD Medical segment had revenues of $897.3 million for the quarter, down around 3 percent from $922.3 million, and including a nearly 5 percent negative impact from currency translation. The BD Diagnostics segment had revenues of 539.6 million, up 1.7 percent from revenues of $530.6 million for the second quarter of 2008, and including a negative foreign currency impact of around 3 percent.
BD's net income for Q2 was $261.3 million, or $1.06 per share, down from $276.2 million, or $1.09 per share, for Q2 2008.
Its R&D expenses increased roughly 3 percent to $98.7 million from $96 million, while its SG&A spending rose 6 percent to $440.5 million from $415.5 million.
BD did not report its cash position as of the end of the second quarter.
The firm expects to report EPS growth of between 7 percent and 9 percent for full-year 2009.